212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?

Detalles Bibliográficos
Autores principales: Javadinia, S.A., Dehghani, M., Ariamanesh, M., Roudsarabi, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069431/
http://dx.doi.org/10.1016/j.annonc.2022.03.233
_version_ 1784700428787646464
author Javadinia, S.A.
Dehghani, M.
Ariamanesh, M.
Roudsarabi, Z.
author_facet Javadinia, S.A.
Dehghani, M.
Ariamanesh, M.
Roudsarabi, Z.
author_sort Javadinia, S.A.
collection PubMed
description
format Online
Article
Text
id pubmed-9069431
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Society for Medical Oncology. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90694312022-05-04 212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome? Javadinia, S.A. Dehghani, M. Ariamanesh, M. Roudsarabi, Z. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2022-05 2022-05-05 /pmc/articles/PMC9069431/ http://dx.doi.org/10.1016/j.annonc.2022.03.233 Text en Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Javadinia, S.A.
Dehghani, M.
Ariamanesh, M.
Roudsarabi, Z.
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
title 212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
title_full 212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
title_fullStr 212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
title_full_unstemmed 212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
title_short 212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
title_sort 212p a cohort study on the immunogenicity and safety of the inactivated sars-cov-2 vaccine (bbibp-corv) in patients with breast cancer: does trastuzumab interfere with the outcome?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069431/
http://dx.doi.org/10.1016/j.annonc.2022.03.233
work_keys_str_mv AT javadiniasa 212pacohortstudyontheimmunogenicityandsafetyoftheinactivatedsarscov2vaccinebbibpcorvinpatientswithbreastcancerdoestrastuzumabinterferewiththeoutcome
AT dehghanim 212pacohortstudyontheimmunogenicityandsafetyoftheinactivatedsarscov2vaccinebbibpcorvinpatientswithbreastcancerdoestrastuzumabinterferewiththeoutcome
AT ariamaneshm 212pacohortstudyontheimmunogenicityandsafetyoftheinactivatedsarscov2vaccinebbibpcorvinpatientswithbreastcancerdoestrastuzumabinterferewiththeoutcome
AT roudsarabiz 212pacohortstudyontheimmunogenicityandsafetyoftheinactivatedsarscov2vaccinebbibpcorvinpatientswithbreastcancerdoestrastuzumabinterferewiththeoutcome

Ejemplares similares